Read More Stock News at Market Barrister
The IPO was subscribed 25x with the base Price of ₹ 111 & listed on exchange on 3-July-2025 with open price of ₹111 and close in red with ₹ 110.35
The stock has surged from ₹110 to ₹116 , the stock closed today at price ₹ 116 , however the stock has touched with ₹ 122 on 22-July-2025.
A newly listed IPO, backed by robust Domestic Institutional Investor (DII) participation, is gaining investor attention with strong post-listing performance. Here’s a closer look at its shareholding dynamics, listing journey, and company profile.
| Stake | Promoter | FIIs | DIIs | Public |
|---|---|---|---|---|
| June 2025 | 96.87% | 0.00% | 0.00% | 3.13% |
| July 2025 | 69.05% | 0.15% | 13.64% | 17.16% |
Originally incorporated as Jai Shree Rasayan Udyog Limited on January 22, 1993, in New Delhi, the Company commenced operations on February 16, 1993. In 2015, it rebranded as Indogulf Cropsciences Limited to align with its core business focus. The name change was approved by the Board and shareholders and formalized through a fresh incorporation certificate on April 28, 2015.
Read more about the stock News on ” Market Barrister “
With operations across 22 Indian states and three Union Territories, and a global presence in over 34 countries, the Company boasts a wide distribution network. It partners with 169 institutional (B2B) clients and 5,772 domestic distributors (B2C), supported by 17 depots, six branch offices, and 129 global partners, backed by a dedicated sales and development team.
Listed on July 3, 2025, at ₹111 (issue price), the IPO was oversubscribed by 25 times. It opened at ₹111 and closed slightly lower at ₹110.35. Since then, the stock has shown strength, climbing to ₹116, with a high of ₹122 recorded on July 22, 2025. The steady upward movement reflects growing investor confidence, especially after the increase in DII shareholding.
Indogulf Cropscience belongs to the of chemical and fertilizers with the market capitalization of 700Cr., Face value ₹10 and, 52W Low ₹101 52W High ₹122, P/E 23.5 , CMP ₹116.51,
The content on ” Market Barrister” is for informational purposes only and does not constitute financial advice. We are not licensed financial advisors or brokers. All information is based on personal opinions and experiences and should not be relied upon for making investment decisions. Investing in stocks and financial markets carries inherent risks, including the potential loss of capital. Always consult with a professional before making any financial decisions. “Market Barrister” is not responsible for any losses or damages resulting from the use of this information. Use the content at your own risk
Power Generation Company Reliance Power Company led by Anil Ambani,Q1 results issued on 19-July-2025 , The Company performed well and delivered the 44Cr. profit than the previous year June Q -97Cr, the profit increases 45% respect to previous year.
Published: 19 July 2025
Company Led By: Anil Ambani
The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication
Trending IPO Season: Over the last ten days, several IPOs have been listed on both NSE and BSE. While some delivered over 50%+ returns with bumper ,trading steadily and continued to trend on both exchanges.
Stock that have listed on NSE-BSE ,how are they performing lets have a look in this BLOG for bumper listed IPOs in last six month.
This is SME IPO listed on both Exchanges NSE-BSE on day of 4-July-2025,IPO Price ₹ 85 , along with strong subscription of 275X strong debut opening price at ₹ 130 and closes at ₹136.50, Company’s MCAP is ₹307 Crore. Listing gain of investor 53%.
Share holding Pattern :Promoters 89.14 % ,FIIs 0.00%,DII 0.00%, Public 10.86%, others 0.00%
Adcounty Media India Limited, founded in 2017 and made public in 2024, is a BrandTech company offering digital advertising solutions. It focuses on AdTech and Digital Marketing, using in-house tools and online platforms to optimize campaigns. Working on a performance-based model, it helps brands across sectors like fintech, e-commerce, travel, and FMCG grow through targeted, result-oriented marketing.
Union Cabinet allocated One Lac Crore for Sunrise Sectors Led with Innovation,Design & Start up etc.
Pharma Company surges 40% in 12 weeks with strong volume, Consistent sales.
This SME IPO was listed on both NSE and BSE on July 4, 2025, at an issue price of ₹75. Backed by a strong subscription of 119x, the stock made an impressive debut, opening at ₹105 and closing at ₹110.25. The company’s market capitalization stands at ₹427 crore. Investors enjoyed a robust listing gain of 40% on the first day.
Share holding Pattern :Promoters 100 % ,FIIs 0.00% ,DII 0.00%, Public 0.00%, others 0.00%
Neetu Yoshi is a metallurgical engineering company specializing in the manufacturing of customized ferrous metal products, including mild steel, cast iron, spherical graphite iron, and manganese steel. their capabilities range from small to mid-sized castings and RDSO-approved vendor for over 25 products used by Indian Railways. Certified with ISO 9001, 14001, and 45001, Neetu Yoshi ensure quality, safety, and sustainability. Their modern infrastructure, skilled workforce, and technical expertise enable them to deliver efficient, cost-effective, and reliable solutions with Client base of Rail Coach Factory Railway , L&T, Ashok Leyland, Texmaco ,BHEL, ACE, Titagarh Railway.
This mainboard IPO was listed on both NSE and BSE on July 2, 2025, at an issue price of ₹746. Despite a modest subscription of 19x, the stock had a strong debut, opening at ₹840.95 and closing the day at ₹841. It is currently trading at ₹845.45, with a market capitalization of ₹70,135 crore. Investors saw a listing gain of approximately 13% on the first day.
Share holding Pattern :Promoters 100 % ,FIIs 0.00% ,DII 0.00%, Public 0.00%, others 0.00%
HDB Financial Services (HDBFS), a subsidiary of HDFC Bank, is a leading NBFC serving individuals and businesses across India. Incorporated in 2007, it is a well-established and financially strong institution. HDBFS offers a wide range of secured and unsecured loans, along with investment and protection solutions. It operates through a network of over 1,700 branches across 27 states and 4 union territories. The company also provides BPO services, including back-office functions like document processing and accounting, as well as front-office services such as contact center management.
This mainboard IPO was listed on both NSE and BSE on July 1, 2025, at an issue price of ₹400. Despite a relatively low subscription of 22x, the stock made a strong debut, opening at ₹492 and closing the day at ₹541. It is currently trading at ₹562, with a market capitalization of ₹7,921 crore. Investors enjoyed a listing gain of 35% on the first day.
Share holding Pattern :Promoters 61.51% ,FIIs 1.29% ,DII 10.76%, Public 17.42%, others 9.02%
Ellenbarrie Industrial Gases Ltd (EIGL) is one of India’s oldest industrial gas companies, with over 50 years of legacy. It is the largest 100% Indian-owned player in terms of capacity and profitability, operating one of India’s largest oxygen plants. EIGL manufactures gases like oxygen, nitrogen, argon, helium, and hydrogen, serving industries such as steel, shipbuilding, pharmaceuticals, and defence. It also supplies synthetic air for environmental testing, playing a vital role in India’s space and defence sectors.
This is SME IPO listed on both Exchanges NSE-BSE on day of 27-June-2025,IPO Price ₹47 ,along with strong subscription of 216.5X the stock debut with opening price at ₹58 and same day closed at ₹ 60,while current trading at price of ₹59.10 ,Company’s MCAP ₹130 Crore. Listing gain of investor was 27%
Share holding Pattern :Promoters 73.53% ,FIIs 3.38%,DII 10.46%, Public 10.89%, others 1.73%
Mayasheel Ventures Limited is an engineering construction company engaged in roads, electrical works, and civil projects. As an “A” class government contractor, it has executes projects on EPC and item-rate bases, including sub-contracting with a strong presence in Uttar Pradesh and the North-East, they have built and have expertise in road and electrical infrastructure, delivering successful projects across various regions.
This is SME IPO listed on both Exchanges NSE-BSE on day of 25-June-2025,IPO Price ₹96 ,along with strong subscription of 187X the stock debut with sky rocket opening price at ₹132 and same day closed at ₹126,while current trading at price of ₹131 ,Company’s MCAP ₹304Crore. Listing gain of investor was 38%
Share holding Pattern :Promoters 73.53% ,FIIs 3.38%,DII 10.46%, Public 10.89%, others 1.73%
Influx, established in 2003, is a leading healthcare contract manufacturer with GMP, HACCP, ISO 22000, and Halal-certified plants. Serving clients across India and 4 continents, it offers innovative, quality-driven products in nutraceuticals, cosmetics, ayurvedic, veterinary, and homecare segments. Capable of large, cost-effective batches in various forms like tablets, capsules, soft gels, powders, liquids, bars, gummies, creams, and more.
This is SME IPO listed on both Exchanges NSE-BSE on day of 24-June-2025,IPO Price ₹128 ,along with strong subscription of 275X the stock debut with Bumper opening price at ₹243 and same day closed at ₹255,while current trading at price of ₹225 ,Company’s MCAP ₹306Crore. Listing gain of investor was 100%
Share holding Pattern :Promoters 61.51% ,FIIs 1.29% , DII 10.76%, Public 17.42%, others 9.02%
Founded in 1977, Eppeltone Engineers is a prominent Indian metering company. Initially focused on SMPS for electronic devices, the company gradually diversified into manufacturing AVR, UPS, MCBs, and transducers. In 1999, responding to India’s infrastructure growth, Eppeltone established modern facilities for energy meter production, strengthening its position as a trusted and versatile manufacturer in the power and electronics sector.
This is SME IPO listed on both Exchanges NSE-BSE on day of 23-June-2025,IPO Price ₹120 ,along with strong subscription of 94X the stock debut with Bumper opening price at ₹155 and same day closed at ₹162,while current trading at price of ₹204 ,Company’s MCAP ₹445 Crore. Listing gain of investor was 30%
Share holding Pattern :Promoters 69.29% ,FIIs 2.93% , DII 7.33%, Public 13.05%, others 7.4%
Founded in 2015, our Automation Division operates five facilities across India. Two Pune-based plants specialize in fixtures and end-to-end automation solutions, including welding lines, assembly systems, auto handling, gantries, and testing SPMs. With a total space of 4,60,000 sq. ft., we are dedicated to delivering high-quality, innovative automation products tailored to diverse industrial needs
This is SME IPO listed on both Exchanges NSE-BSE on day of 19-June-2025,IPO Price ₹143 ,along with strong subscription of 170X the stock debut with Bumper opening price at ₹231 and same day closed at ₹243,while current trading at price of ₹309 ,Company’s MCAP ₹672 Crore. Listing gain of investor was 61%,
Share holding Pattern :Promoters 73.61% ,FIIs 5.81% , DII 5.74%, Public 11.03%, others 3.81%.
Founded in 2018, Monolithisch India Limited is a leading manufacturer of high-quality premixed ramming mass, used in induction furnaces for secondary steel production. As part of the Mineral Group, it supplies over 80% of integrated steel plants in India, playing a vital role in boosting furnace efficiency and supporting some of the country’s fastest-growing steel enterprises.
This is SME IPO listed on both Exchanges NSE-BSE on day of 16-June-2025,IPO Price ₹102 ,along with strong subscription of 291X the stock debut with Bumper opening price at ₹153 and same day closed at ₹160,while current trading at price of ₹159 ,Company’s MCAP ₹672 Crore. Listing gain of investor was 50%,
Share holding Pattern :Promoters 71.54% ,FIIs 1.46% ,DII 12.81%, Public 12.55%, others 1.67%.
Sacheerome is a passionate team of innovators and creators crafting fragrances and flavours that evoke emotions and awaken memories. With roots tracing back to the early 1900s, our journey has been driven by creativity and excellence. Today stands as one of the leading manufacturers and suppliers of concentrated fragrances and flavours, setting benchmarks across the industry.
The content shared on Marketbarrister is for informational and educational purposes only. All articles, analysis, charts, opinions, and insights reflect personal views and interpretations based on self-study, publicly available information, and market trends.
We are not SEBI-registered advisors, and none of the content on this blog should be considered as investment, trading, legal, or financial advice. Readers are strongly advised to do their own research or consult with a certified financial advisor before making any investment decisions.
While we strive to provide accurate and timely information, Marketbarrister does not guarantee the completeness, reliability, or accuracy of any data or views shared. Markets are subject to risk, and past performance is not indicative of future results.
By using this blog, you acknowledge and agree that Marketbarrister and its contributors are not liable for any loss or damage arising from the use of the content
Natco Pharma has delivered an impressive 40% return in just 12 weeks, climbing from ₹726 to ₹1,000. With improving financials and strong trading volumes, the stock continues to show sustained momentum.
Natco Pharma Limited, headquartered in Hyderabad, was established in 1981 with an initial capital of ₹3.3 million. The company is a prominent Indian pharmaceutical player engaged in the production of active pharmaceutical ingredients (APIs) and finished dosage formulations. Its business operations span multiple segments, including bulk chemicals, finished formulations, retail pharmacy, and contract manufacturing (job work).
Natco Pharma Why declined in Sep 2024 from ₹1639 to ₹726
Suzlon is next GEM in Renewable Energy , Price Trend up , Surging Monthly volume
In the oncology space, Natco offers a wide range of products such as Desifer, Veenat, Bendit, Bortenat, Lenalid, and Clokeran. In the broader pharmaceutical segment, its key offerings include T-Score, PT-MaX, Glatimer, Tarana, and Tigi.
Stock 52W low ₹726 ,52W High ₹1639 with market capitalization of ₹ 17885 Cr and PE 9.49 and Sector PR 39.22
Net Revenue collection in Q4 FY2025 stood at ₹1,287 crore, compared to ₹1,110 crore in Q4 FY2024.
Net profit rose to ₹406 crore in Q4 FY2025, up from ₹386 crore in the same quarter of the previous financial year.
Natco Pharma has shown a consistent upward trend over the past three years, reflecting the company’s strong financial position and earnings retention.
FY2025: ₹7,571 crore
FY2024: ₹5,817 crore
FY2023: ₹4,837 crore
Natco Pharma has delivered the marvelous performance in last three year which shows the strength and confidence by investors in the Company.
FY2025: 57.57
FY2024: 47.00
FY2023: 38.42
FY2025: 57.27
FY2024: 42.33
FY2023: 32.37
Natco Pharma delivered the good performance continuous improvement in performance and progress Export-focused auto and pharma stocks saw notable gains on July 3, driven by market optimism over a potential India-US trade deal expected to be announced soon.
The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication.
New Delhi, July 1, 2025 — The Union Cabinet allocated One Lack Crore to strengthen science, technology, research, development, innovation, and design the electronics in India. India is emerging and entering in new era that will not only boost innovation and electronics manufacturing but also create more job opportunities. This initiative will pave the way for a self-reliant, self-innovative, and self-manufacturing India, positioning the country as a global technology leader & mark the position on world Map.
Under the scheme, the “Anusandhan National Research Foundation” (ANRF) Executive Committee will play a key role in providing direction, guidelines, and defining the scope of projects in emerging and sunrise sectors. These sectors include green energy, agriculture, medical equipment, startups, innovation, robotics, and electronic design etc. The initiative aims to position India not just as an assembler but as a leading manufacturer and global supplier of innovative products. With this push, India is set to become a hub for high-end manufacturing and research-driven innovation, strengthening its position on the global technology and industrial map.
The electronics industry is growing rapidly across the globe, becoming an essential pillar of modern life. In today’s digital era, living without electronic devices and connectivity is nearly impossible, as they have transformed how we live, work, and communicate. The COVID-19 pandemic further accelerated this shift, making digital integration and reliance on electronic gadgets even more critical. As the world moves deeper into digitalization, the demand for innovative electronic products continues to rise, driving both production and economic growth. Although India had aimed to generate ₹400 billion in electronics revenue by 2025, the pandemic impacted these projections. However, the country now targets ₹300 billion in revenue by the end of 2025, reaffirming the sector’s role as a key engine for future growth.
India launched the National Green Hydrogen Mission on February 4, 2023, with the goal of establishing itself as a global hub for the production, export, and manufacturing of green hydrogen. Backed by a central government budget of INR 197.44 billion (US$2.37 billion), the mission focuses on promoting sustainable energy and reducing carbon emissions. A significant portion—US$2.1 billion—has been allocated to the Strategic Interventions for Green Hydrogen Transition (SIGHT) Programme, which offers incentives for green hydrogen production. The mission targets the production of 5 million metric tonnes per annum (MMTPA) of green hydrogen by 2030, positioning India at the forefront of the global green energy transition.
India’s electric mobility drive, supported by FAME II and 100% FDI, is unlocking major investment opportunities. With over 12,000 EV charging stations and a target to electrify 30% of vehicles by 2030, the sector is primed for growth. Rising two-wheeler EV registrations and the PLI Scheme for Advanced Chemistry Cells boost local battery manufacturing, lowering costs and improving competitiveness. Investors can tap into this green transition while benefiting from strong returns and contributing to a sustainable future.
Initiatives such as the Pradhan Mantri Kisan Sampada Yojana and liberalized FDI norms are unlocking attractive investment opportunities for both domestic and global investors in India’s agriculture and food processing (A&FP) sector. With a focus on boosting agricultural productivity and strengthening food processing capabilities, the sector offers immense potential for value addition and exports. The PLI Scheme for Food Processing further encourages investment in advanced infrastructure and technology. Supported by improved logistics and digital trading platforms, India’s A&FP sector is well-positioned for sustainable growth and global integration.
India’s healthcare and pharmaceutical sector stands at the intersection of innovation and growth, fuelled by rising healthcare expenditure, technological advancements, and strong government support. The medical technology (medtech) industry alone is projected to reach $50 billion by 2025, offering vast investment opportunities across diagnostics, devices, and digital health.
Strategic advantages such as skilled talent, cost efficiency, and the Make in India initiative are attracting manufacturers and investors alike. As India is poised to become the world’s third-largest economy by 2030–31, the healthcare and pharma sectors will be key drivers of this growth.
The biotechnology sector harnesses living organisms, biological systems, and innovative processes to create solutions in healthcare, agriculture, and environmental management. Spanning fields such as vaccine development, genetic modification, biofuels, and sustainable farming, biotechnology plays a crucial role in tackling global issues like disease control, food scarcity, and climate change.
India’s biotech industry is witnessing rapid expansion, fuelled by cutting-edge research and innovation across multiple domains. With a strong focus on medical breakthroughs, agricultural advancements, and eco-friendly technologies, India has emerged as a key player in the global biotech landscape. It currently ranks third in Asia for biotechnology capabilities and boasts a thriving startup ecosystem that continues to attract investment and foster innovation.
other sectors are Artificial intelligence, Petrochemical, Sports Industry, Auto Parts Industry, Capital Goods Production, Defence Manufacturing , Leather Goods Production, Banking, Fintech & Financial Services, Automobile Production and any more are under innovation.
The information provided on this website is for educational and informational purposes only and should not be considered as financial, investment, or trading advice. All content, including stock analyses, market data, and opinions, is based on publicly available information believed to be accurate at the time of publication.
Mazagon Dock A Government Undertaking Shipbuilding Navratna Company with market valuation of 130,868 Crore, Established in 1960 , Till date delivered 805 Vessel, 30 Warships & 8 submarines National & International Clients, MDL also delivered cargo ship, passengers ship, water tankers, tugs dredgers , barges, wellhead platform decks & process platform etc.
Yes Bank is seeing improvement in its NPA and an increase in profits.
Read more stock news on equitybsense.blogspot.com
Stock price surged 60% in last 20 weeks , In Feb stock was trading at ₹ 2131 and reached to ₹ 3775 in May, delivered a robust growth, Stock split in 1:2 Ratio. Stock has a new face value of ₹ 5 , if anyone having 10 share , he will get 10 more share, total share now will be 20 Numbers.
The acquistion process will going to complete within four to six month and the value of acquistion will not exceed $52.96 mn, this includes the primary & secondary , upon completing formalities the Mazagaon Dock will have controlling stake with equity holding of 51% stake & Mazagaon will take control of CDPLC and this became subsidiary of Mazagaon Ship Building.
Mazagon stated that the proposed acquisition is aimed at strengthening its foothold in the ship repair and shipbuilding sectors by leveraging operational synergies, enhancing R&D capabilities, and expanding market presence in line with its long-term growth strategy. According to the DFC( Development Finance Corporation ), the port is the largest and busiest transshipment hub in the Indian Ocean and has been operating at over 90% capacity since 2021, highlighting the need for an additional terminal to meet growing demand.
the article reference taken from the ship technology
Mazagon Deck Acquire Colombo Dockyard
Dec 2024 & March 2025
Promoter Stake 83.83% 84.83%
FII Stake 1.55% 2.26%
DII Stake 1.47% 1.7%
Public Stake 10.48% 9.56%
Total Sales ₹3103 Cr. ₹3174 Cr.
Total Profit ₹654 Cr. ₹326 Cr.
With the acquisition expected to be completed in the next 4 to 6 months, control over business and operations will open new global avenues and unlock greater business opportunities. This is anticipated to enhance both the company’s valuation and overall worth in the future.
Mazagoan dock is the only company of INDIA which is so much diversified and has the Client of India and Global Ample.
The content shared on Marketbarrister is for informational and educational purposes only. All articles, analysis, charts, opinions, and insights reflect personal views and interpretations based on self-study, publicly available information, and market trends.
We are not SEBI-registered advisors, and none of the content on this blog should be considered as investment, trading, legal, or financial advice. Readers are strongly advised to do their own research or consult with a certified financial advisor before making any investment decisions.
While we strive to provide accurate and timely information, Marketbarrister does not guarantee the completeness, reliability, or accuracy of any data or views shared. Markets are subject to risk, and past performance is not indicative of future results.
By using this blog, you acknowledge and agree that Marketbarrister and its contributors are not liable for any loss or damage arising from the use of the content.
Thanks
Natco Pharma 52 Week Week High ₹ 1639
Natco Pharma 52 Week Week Low ₹ 726
The Company declined from the Highest of ₹ 1639 to ₹ 726 in previous , However the stock is declining from the Sep-2024 due to the global uncertanity but the stock dropped heavily in December post Q3Y25.
The decline was primarily due to a sharp drop in export formulation sales, which fell from ₹605 crore in Dec-23 to ₹286 crore in Dec-24—a 53% decrease. This was largely driven by a significant reduction in Revlimid sales, the company’s main revenue contributor, which had a substantial impact on overall financial performance.
Read More on Market Barrister
EaseMyTrip is the 2nd largest Online Travel Platform in India founded in 2008
Natco Pharma’s Q4 FY2025 financial results have shown strong performance. The stock has also recorded a notable improvement compared to Q3 FY2025.
Total sales for Q4 FY2025 stood at ₹1,221 crore, compared to ₹1,068 crore in the same quarter last year, marking a solid year-on-year growth. Notably, the company reported a remarkable 200+% increase in Profit After Tax (PAT), reaching ₹406 crore in Q4 FY2025, up from ₹132 crore in Q3 FY2025.
Natco Pharma Limited is a vertically integrated and innovation-led pharmaceutical company engaged in the development, manufacturing, and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). With a strong focus on niche therapies and complex generics, Natco has established a presence in over 50 countries.
The company markets its FDF products across key regions including the United States, India, Europe, and other international markets, and operates in select geographies through its subsidiaries. Natco has built a strong reputation as a reliable, high-quality manufacturer of niche Active Pharmaceutical Ingredients (APIs), with a track record of producing over 50 APIs. While oncology remains our primary therapeutic focus, broadening our portfolio to include products in Central Nervous System (CNS) disorders, pain management, and cardiovascular care. Natco consistently creates first-to-market opportunities for its partners and customers.
Natco-Pharma
The chart looks attractive on monthly basis, However after making a low of ₹ 757 the stock gain the break out in the upward direction with the strong volume , Stock has gained the momentum of 20% in last three months and performing good on NSE & BSE.
Over the past year, Natco Pharma has consistently delivered strong performance and maintained healthy profitability. In the most recent quarter, the company recorded a remarkable increase in sales, accompanied by a sharp surge in Profit After Tax (PAT). This robust financial performance is further reinforced by a significant rise in trading volumes on the monthly charts, reflecting strong market confidence.
Vedanta Demerger in five Verticals-Promoters stake 100% Pledge & Q3Y24 Result
Suzlon highlighted that the installed capacity as of March 2025 stands at 475 GW. The projected target is 777 GW by 2030 and 2,100 GW by the year 2047 including wind, power, solar ,hydro also whereas the major part comes from the SOLAR projects.
Market Cap ₹ 97,742 Cr.
PE: 46.7
ROCE: 32.4 %
52W low: ₹44.30
52W high: ₹86.04
Currently, the stock is trading on NSE ,BSE at ₹71.48, Stock reached highest in September 2024 ₹ 86 .04
Suzlon Energy Reports Strong Growth with Robust Order Book and Financial Performance
Suzlon Energy continues to strengthen its position in the renewable energy sector, maintaining a robust order book across both solar and wind energy segments. The company recently secured significant wind energy orders including:
100.8 MW from Sunsure Energy
378.0 MW from NTPC Green Energy
50.4 MW from Bharat Petroleum Corporation Limited (BPCL)
As of May 2025, Suzlon’s total wind energy order book stands at an impressive 5,555 MW, with several additional projects currently in the pipeline.
On the financial front, Suzlon has demonstrated substantial year-on-year (YoY) growth:
Revenue rose from ₹2,179 crore in Q4 FY24 to ₹3,774 crore in Q4 FY25, reflecting a 73% YoY increase.
Profit After Tax (PAT) surged from ₹281 crore in Q4 FY24 to ₹1,181 crore in Q4 FY25, marking a remarkable 320% YoY growth.
EBITDA for Q4 FY25 stood at ₹693 crore, contributing to a full-year EBITDA of ₹1,857 crore.
These results underscore Suzlon Energy’s strong operational performance and its growing role in India’s transition to sustainable energy.
Suzlon has shown the good number and the Company execution has good execution strategy and the growth showing the good number QoQ, with 30% cumulative market share and the provides the best in class of maintenance services for their customer.
GoI vision of to complete the 500 Gwatt by 2030 , This shows that Government of India has started work on developing energy corridor not today but the work started in the year of 2015 itself, Since than work has started on war front basis and many project were delivered across many states of India and yet more progress to be achieved in next years.
Suzlon Energy is recognized as India’s leading company in wind Operations & Maintenance (O&M), backed by a structured escalation clause of 4–5% in service fees. With a strong growth trajectory and a rapidly expanding order book, Suzlon is well-positioned to emerge as the undisputed leader in the wind energy sector. The company’s robust performance and future pipeline underscore its dominant role in driving India’s wind-based renewable energy landscape.
Market Barrister
Why Gensol Engineering Company Stock Price falling from its high of INR 1376
Natco Pharma declined from its lifetime high of INR 1639 to INR 726.
More growth yet to happen in all the sectors of :Manufacturing Metal and Mines, EPC ,Design and Consultancy Services and Indian economy is on the verge of next era.
Ramkrishna forge since previous QoQ the share holding pattern is attractive and the increase in volume catching the investor attention on the stock, Ramkrishna consistently delivered good results
The chart shows the shareholding pattern for the period of Dec to March. Increase in share holding pattern of Ramkrishna forge shows the strength in stock.
The Company half yearly results consistently delivering the good performance and the profit seems promising also attractive .
Read more about stock on Market Barrister
Dec’2024 Q period results has improved from the pervious Dec’2023 and profit is marginally increased ,EBIT is increased ,however the Mar’2025 result is awaited.
This week, trading volume has been steadily increasing, with the average daily volume over the past few days reaching approximately 600,000
Ramkrishna Forgings Limited, incorporated in 1981 and headquartered in Kolkata, manufactures forged components for sectors including Automotive, Railways, Oil & Gas, and Construction. As of December 31, 2024, its installed capacity stood at 229,150T, supported by advanced facilities in Jamshedpur and global offices in the USA, Mexico, Europe, and Turkey. It supplies critical components for railway systems and is a preferred supplier to OEMs like Tata Motors, Ashok Leyland, Daimler, and global brands such as Volvo, Iveco, Scania, and Dana. The company has expanded into machining, heat treatment, and isothermal annealing, enabling full-service manufacturing for Tier 1 customers. It is certified under TS 16949, OHSAS 18001, and ISO standards
The advises and discussion given is for learning purpose only , we don’t advice or recommend anyone to invest in the market. For any investment ,discuss with your finance advisor.